ASCRS 2023: Harrow to launch FDA-approved chloroprocaine hydrochloride ophthalmic gel for ocular surface anesthesia

Article

According to the company, clinical trials of the ophthalmic gel showed that patients treated with IHEEZO did not require any supplemental treatment to complete the intended surgical procedure. Harrow will host several launch events at the 2023 American Society of Cataract and Refractive Surgery annual meeting being held May 5-8, 2023, in San Diego, California.

Harrow today announced the launch of FDA-approved IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting being held May 5‑8, 2023, in San Diego, California.

According to the company, IHEEZO is a sterile, single-patient‑use, physician‑administered, ophthalmic gel preparation, containing no preservatives, that is safe and effective for ocular surface anesthesia. It was approved by the FDA on September 26, 2022.

Moreover, the clinical trials of the ophthalmic gel showed that patients treated with IHEEZO did not require any supplemental treatment to complete the intended surgical procedure. The company also noted in its news release that the gel represents the first approved use in the U.S. ophthalmic market of chloroprocaine hydrochloride and the first branded ocular anesthetic approved for the U.S. ophthalmic market in nearly 14 years. It also is protected by an Orange Book-listed patent that is valid until 2038.

The company noted that IHEEZO is indicated for ocular surface anesthesia. It is contraindicated in patients with a history of hypersensitivity to any component of this preparation.

IHEEZO has been issued a J‑Code (J2403) and transitional pass-through reimbursement status by the Centers for Medicare & Medicaid Services (CMS).

Launch events

  • Richard L. Lindstrom, MD, will be making a presentation titled, Prospective, Randomized Comparison of Chloroprocaine 3% Gel and Tetracaine 0.5% Solution for Cataract Surgery Anesthesia. The presentation is scheduled during the Medications (Preoperative, Postoperative, Intraoperative) session on Sunday, May 7, beginning at 3:40 p.m. PT in the SDCC, Upper Level, Room 5A.
  • William Wiley, MD, will speak about his experience using IHEEZO during a booth talk scheduled to begin at 1:30 p.m. PT at Harrow’s booth #2237 on Saturday, May 6.
  • Harrow will host the “Harrow Brings Nashville to San Diego” IHEEZO Launch Event at the Hard Rock Hotel in downtown San Diego from 5:30-7:30 p.m. on Saturday, May 6.
Recent Videos
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
What was the biggest innovation in eye care in 2024?
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
© 2024 MJH Life Sciences

All rights reserved.